Verbatim response from Perplexity
For blood clot safety, the patch is generally safer than the pill for menopausal estrogen therapy, because transdermal estrogen is associated with lower venous thromboembolism (VTE) risk and less liver-related clotting-factor stimulation than oral estrogen.[1][2][13][16]
A practical way to think about it:
- Patch: usually preferred if you have higher clot risk, migraine with aura, high triglycerides, liver concerns, or other cardiovascular risk factors.[1][2][9][14]
- Pill: still a reasonable option for many healthy women under 60 with no major clot risk factors, and it may be less expensive and simpler to use.[2][14]
What the evidence says:
- Multiple observational studies and reviews report that oral estrogen increases VTE risk, while transdermal estrogen does not show the same increase in those datasets.[1][2][5][7][13][16]
- Major guidance summarized in the search results says transdermal estradiol may be preferred when thrombotic or cardiovascular risk is elevated.[2][9]
Important caveat:
- “Safer” depends on which risk you mean. The search results mainly support the patch as safer for blood clots; they do not show a broad, universal safety advantage for every outcome.[8][18]
- For an individual decision, your clinician should consider your age, smoking status, clot history, blood pressure, triglycerides, migraine history, and whether you also need a progestogen if you still have a uterus.
If you want, I can also give you a patch vs pill comparison by risk category: clots, stroke, breast cancer, triglycerides, and convenience.